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Alteration of single genes involved in nutrient and lipoprotein metabolism increases longevity in several animal
models. Because exceptional longevity in humans is familial, it is likely that polymorphisms in genes favorably
influence certain phenotypes and increase the likelihood of exceptional longevity. A group of Ashkenazi Jewish
centenarians (n ¼ 213), their offspring (n ¼ 216), and an age-matched Ashkenazi control group (n ¼ 258) were
genotyped for 66 polymorphisms in 36 candidate genes related to cardiovascular disease (CVD). These genes were
tested for association with serum lipoprotein levels and particle sizes, apolipoprotein A1, B, and C-3 levels and with
outcomes of hypertension, insulin resistance, and mortality. The prevalence of homozygosity for the  641C allele in
the APOC3 promoter (rs2542052) was higher in centenarians (25%) and their offspring (20%) than in controls (10%) (p¼
0.0001 and p¼0.001, respectively). This genotype was associated with significantly lower serum levels of APOC3 and a
favorable pattern of lipoprotein levels and sizes. We found a lower prevalence of hypertension and greater insulin
sensitivity in the 641C homozygotes, suggesting a protective effect against CVD and the metabolic syndrome. Finally,
in a prospectively studied cohort, a significant survival advantage was demonstrated in those with the favorable 641C
homozygote (p , 0.0001). Homozygosity for the APOC3 641C allele is associated with a favorable lipoprotein profile,
cardiovascular health, insulin sensitivity, and longevity. Because modulation of lipoproteins is also seen in genetically
altered longevity models, it may be a common pathway influencing lifespan from nematodes to humans.
Citation: Atzmon G, Rincon M, Schechter CB, Shuldiner AR, Lipton RB, et al. (2006) Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS
Biol 4(4): e113.
Introduction
Manipulation of single genes can confer longevity in lower
organisms, supporting the notion that understanding path-
ways for exceptional longevity may be possible in humans.
Because the contribution of genetics to lifespan is estimated
to be only ;20%, a way to enhance the odds of identifying
genetic factors is to study those with very exceptional survival
[1]. Favorable modulation of aging processes and disease
susceptibility is strongly inherited in families with excep-
tional longevity [2,3]. Current centenarians have survived to
more than double their life expectancy at birth, and have
often been spared from age-related diseases, speciﬁcally
cardiovascular disease (CVD), Alzheimer disease, diabetes
mellitus (DM), and cancer [4]. Furthermore, evidence suggests
that the offspring of centenarians may inherit protection
against major causes of mortality, because they have
approximately 50% lower prevalence of these major diseases
than control groups [5].
Because of the strong heritability of this survival advantage,
we began a search for gene variants that could explain the
extended life of centenarians and their families among a
genetically homogeneous population of Ashkenazi Jews.
Crucial to our approach is the knowledge that only 1/10,000
survives to 100 y, while the average lifespan in the US is ;77
y. Thus, enrichment in the frequency of certain gene variants
at extreme old age probably reﬂects a selection effect that
increases the likelihood of survival. Here we test if poly-
morphisms in certain candidate genes are signiﬁcantly more
frequent in centenarians than in younger participants. Given
that the extreme old age of the probands precludes the use of
a proper age-matched control group for analysis of traits that
may be related to exceptional longevity, (e.g., lipoprotein
levels), we also recruited their offspring, many of whom
presumably inherited longevity gene variants and thus should
also manifest the longevity phenotype. We reasoned that this
approach would permit comparison of the offspring to age-
matched controls who would not be expected to be enriched
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PLoS BIOLOGYwith longevity gene variants, thereby accounting for period
and cohort effects and phenotypic variation that may occur
at older age [6].
We recently reported that lipoprotein particle sizes are
increased in centenarians and their offspring, and suggested
that this trait may increase the likelihood of attaining
exceptional longevity [6]. This phenotype was also associated
with approximately a 3-fold increased frequency of homo-
zygosity (valine–valine [VV]) of a common functional variant
(I405V) in the cholesterol ester transfer protein (CETP) gene,
and decreased CETP levels. Further, through a genome-wide
scan, Geesaman and coworkers found increased frequency of
polymorphisms in the microsomal transfer protein in
centenarian sibling pairs but not in other populations [7].
Here we implicate a polymorphism in the apolipoprotein C3
gene (APOC3), yet another gene regulating lipoprotein
metabolism, in human longevity. We further report associa-
tion of this same polymorphism with decreased serum
apolipoprotein C3 (APOC3) levels, and favorable lipoprotein
proﬁle, outcomes of age-related disease, and lifespan.
Results
We reasoned that due to selective mortality, favorable
genotypes will be present at higher frequency among
centenarians than in younger controls. We studied 66 single
nucleotide polymorphisms (SNP) in 36 candidate genes in
pathways related to lipoprotein metabolism and other risk
factors for CVD. After applying the Bonferroni correction for
multiple comparisons, two of the associations with excep-
tional longevity remained statistically signiﬁcant. Analysis of
the frequency trend with age (in centenarian and control
groups combined) for polymorphisms in APOC3 and CETP
(Figure 1), revealed a highly signiﬁcant (p , 0.0006; b ¼ 1.89
[95% CI, 0.2–3.6]) monotonically increasing frequency trend
for homozygosity for the APOC3  641 C allele
(CC)(rs2542052), and near-signiﬁcance (b ¼ 3.06 [95% CI,
0.33–5.8, p¼0.069]) for homozygosity for the CETP codon 405
valine allele (VV)(rs5882). The CC genotype at position  641
of APOC3 had a prevalence of 25% among the centenarians
and 20% in their offspring compared with only 10% in
controls (p ¼ 0.0001 and p ¼ 0.001, respectively). Five
additional SNPs in APOC3 and six SNPs in CETP (Figure 2)
showed no evidence of association with longevity. Conversely,
the prevalence of the APOC3 AA genotype was reduced in
both centenarians and their offspring compared with con-
trols (p ¼ 0.001 both) (Figure 3A).
Linkage disequilibrium (LD) analysis of the CETP gene
revealed that the single nucleotide polymorphism rs1800776
was in LD with rs1800775 just 2 bp apart (D9¼0.94; r
2¼0.20)
(Figure 2). Haplotype analysis with these two SNP revealed
that the C-A haplotype was statistically signiﬁcantly more
prevalent among individuals in the control group compared
with centenarian probands (0.355 versus 0.278, p ,0.004). LD
analysis revealed LD across the neighboring apolipoprotein
A4 (APOA4) and apolipoprotein C3 (APOC3) genes as
previously reported by others (Figure 2) [8]. In haplotype
analysis, the prevalence of the A-C haplotype (corresponding
to SNP rs675 in APOA4 and rs2542052 in APOC3) was
signiﬁcantly higher among the centenarian probands com-
pared with controls (0.498 versus 0.344, p , 10
 8). The
prevalence of the A-A haplotype of the same SNPs was
signiﬁcantly higher among the control group compared with
probands (0.483 versus 0.307, p , 10
 10). Association analysis
between various haplotypes of the APOC3/APOA4 and lipid
proﬁle was not signiﬁcant, neither when the most prevalent
haplotypes in the two groups were compared, (CA versus AA)
nor the haplotypes that contain the favorable APOC3 allele.
The only trend for association (p , 0.07) between haplotype
and lipoprotein was for LDL. This suggests that the single
genotype APOC3 CC is more prominent in the phenotypes.
APOC3 and CETP encode gene products involved in
lipoprotein metabolism and thus the favorable alleles show-
ing monotonic increases in allele frequencies among older
age strata would also be expected to be associated with a
favorable lipoprotein proﬁle. Indeed, participants of all
groups carrying the APOC3  641 CC genotype had lower
serum levels of APOC3 compared with those carrying either
CA or AA (CA/AA) genotype (mean [SE]: 10.1 [1.1] versus 13.2
[1.1] mg/dl, p , 0.05). Given the higher prevalence of this
genotype in centenarians, it is therefore not surprising that
serum levels of APOC3 were lower in centenarians and their
offspring than in controls (mean [SE]: 9.8 [0.6], 9.3 [0.5] versus
11.7 [0.7] mg/dl; p , 0.05 and 0.01, respectively) (Figure 3B).
Relationships between other lipoprotein traits and APOC3
 641 CC genotype are shown in Table 1. Due to the
dependency of lipoprotein traits on age and their modiﬁ-
ability with medications, we only considered offspring (n ¼
131) and controls (n ¼ 126) not using lipid lowering drugs in
this analysis. In females, triglycerides (TG), high density
lipoprotein cholesterol (HDL), and their ratio, as well as low
density lipoprotein cholesterol (LDL) lipoprotein particle
size were signiﬁcantly more favorable among those with the
Figure 1. Distribution of ‘‘Favorable’’ Gene Polymorphisms of APOC3,
APOA4, and CETP in the Study Population
The genotype frequencies of the favorable gene polymorphisms of
APOC3 C( 641)A and CETP I405V were analyzed in controls and probands
(60 to 100 y old). (Offspring were not included in this analysis due to the
genotype dependency of this group on proband genotypes.) The
frequency of these two variants was found to be higher among
centenarians, with a monotonic increase with age. Other polymorphisms
in these same genes (APOC3 ( 455) TT, APOA4 347 TT, and APOA4 360 EE)
showed no differences in genotype frequency with age.
DOI: 10.1371/journal.pbio.0040113.g001
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Conserved Pathway for Extreme LongevityCC genotype compared to the CA/AA genotypes. The same
trends were observed in most of the associations in men.
Since there was no signiﬁcant interaction between gender
and genotypes, we present also the combined group of
females and males and their signiﬁcance. As shown in Table 1
the combined group also exhibited signiﬁcant associations
with lipoproteins according to APOC3 CC genotype.
Given that insulin resistance is associated with lipid
abnormalities, CVD, and death in the elderly [9], we estimated
insulin sensitivity using the homeostatic model assessment
[10]. The favorable APOC3  641 CC genotype was associated
with greater insulin sensitivity in the combined offspring/
control group (p , 0.05, both male and female) (Figure 4A).
The most prevalent CVD marker in an aging population is
progressive increase in blood pressure. Therefore, this trait
was examined in our participants as a surrogate for vascular
aging. The prevalence of hypertension (as deﬁned in the VII
Report of the Joint National Commission on Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure) [11] was signiﬁcantly lower among those with the APOC3
Figure 2. Haplotype Structure of APOC3 and APOA4 and CETP
Ordinal arrangement of 15 SNP associated with CVD and lipoprotein
metabolism, according to their position on chromosomes with LD
(number in boxes) where the highest rate is represented in red and no
LD in lilac. Blocks define potential haplotypes between two clustered
genes.
(A) APOC3 and APOA4.
(B) CETP.
DOI: 10.1371/journal.pbio.0040113.g002
Figure 3. Genotype Distribution of APOC3 C( 641)A and Serum APOC3
Concentrations
(A) APOC3 C( 641)A.
(B) Serum APOC3.
*p , 0.05, ** p ¼ 0.001 versus control.
CC, homozygous for ( 641) C; AA, homozygous for ( 641) A; CA,
heterozygous for ( 641) C/A.
DOI: 10.1371/journal.pbio.0040113.g003
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Conserved Pathway for Extreme Longevity 641 CC genotype than among those with CA/AA genotypes
(p ¼ 0.04) (Figure 4B). Since existing CVD can lead to
reductions in blood pressure, we repeated the test after
excluding all participants with CVD from the analysis. Still,
hypertension was less prevalent in those with the favorable
APOC3 CC genotype (prevalence of hypertension in partic-
ipants carrying the APOC3 CC genotype was 28.6% compared
with 44% in the CA/AA group, p ¼ 0.026). Other known
variants of the APOC3 gene: C( 482)T, T( 455)C, C1100T,
C3175G, and T3206G, (rs2854117, rs2854116, rs4520, rs5128,
and rs4225, respectively) were not associated with TG levels,
insulin sensitivity, or blood pressure.
Of the 381 participants we have genotyped since 1998, 64
had the CC genotype. To describe the relationship between
genotype and death, we plotted the Kaplan-Meier survival
function estimates of study participants by APOC3 genotype
(Figure 5). Survival was signiﬁcantly greater among CC
genotype carriers (p ¼ 0.0007).
Discussion
APOC3 is a major component of very low density lip-
oproteins and chylomicron remnants; it is also a minor
component of HDL [8]. In vitro, it has been shown to inhibit
the activity of lipoprotein lipase, resulting in delayed TG
clearance from plasma [12]. Several studies have shown that
various polymorphisms of the APOC3 gene either within the
promoter region, in particular the T-455C variant poly-
morphism in the insulin response element, or in the gene, are
associated with elevated TG levels but not with signiﬁcant
change in APOC3 levels [13–17]. Previous studies have also
associated high levels of APOC3 with macrovascular and
microvascular disease and their risks. Increased APOC3 levels
were a signiﬁcant indicator of coronary risk in men and in
patients with metabolic syndrome. In particular, those with
vascular disease and metabolic syndrome had a markedly
increased probability of coronary heart disease in an allele-
speciﬁc way [19], and in patients with type 2 diabetes
predisposition [20]. While few studies have correlated both
unfavorable APOC3 promoter genotypes and high APOC3
levels with outcome [21,22], our study is the ﬁrst to our
knowledge to implicate a genotype with low levels of APOC3
and a favorable lipid phenotype with better outcomes related
to longer lifespan. Murine models expressing one to 100
copies of the human APOC3 gene had high levels of APOC3
and were hypertriglyceridemic [23]. APOC3 knockout mice
show absent or decreased APOC3 protein with reduced TG
levels [24], even in the presence of streptozotocin-induced
diabetes [25]. The impact on lifespan has not, however, been
determined in these models.
We hypothesized that since only one out of 10,000 people
in the general population has survived to 100 y, there should
be potent enrichment for favorable genotypes in this unique
population. The monotonic, progressive over-representation
of the APOC3  641 CC genotype with increasing age, from a
relatively infrequent 10% at age ;60 y to 25% in individuals
surviving to age ;100 y is statistically robust and provides
evidence that this genotype provides a selective advantage for
survival to exceptional old age. Underlying population
stratiﬁcation could be responsible for genotypic associations
detected in case-control studies, but this is much less likely in
this relatively homogeneous Ashkenazi population. Further-
more, we demonstrated association of this same genotype
with survival in a prospectively followed cohort. Finally, the
prevalence of heterozygosity for recessive disease alleles
(nearly) unique to the Ashkenazi population, e.g., breast
cancer and Tay-Sachs disease, did not differ signiﬁcantly
between longevity cases and controls, suggesting the lack of
population stratiﬁcation (unpublished data).
In addition to showing statistical associations of the APOC3
genotype with exceptional longevity, we found signiﬁcant
associations between this genotype and several intermediate
longevity-associated traits directly related to lipoproteins.
Table 1. Comparison of Lipoprotein Traits in Females, Males, and All (Combined Offspring and Control Group) Who Were Not on Lipid-
Lowering Drugs by APOC3 C( 641)A Genotype
Phenotype APOC3 Control and Offspring
Female Male Female and Male
CC CA/AA p-Value CC CA/AA p-Value p-Value versus CA/AA
Number 32 124 20 83
Age (y) 67.8(8.6) 68.3(9.2) 0.75 71.8(1.3) 74.3(0.9) 0.22 0.99
BMI (Kg/m
2) 24.9(0.5) 25(0.3) 0.91 25(0.6) 26.3(0.4) 0.12 0.14
HDL (mg/dl) 73.8(2.77) 64.5(1.5) 0.005 56.9(4.1) 51.5(1.7) 0.18 0.004
TGL (mg/dl) 136(10.5) 132(5.3) 0.79 114(15.5) 108(4.9) 0.63 0.93
TG/HDL 1.5(0.2) 2.0(0.1) 0.03 2.22(0.4) 2.34(0.1) 0.72 0.01
VLDL (mg/dl) 68.6(9.12) 68.3(4.82) 0.98 56.6(8.3) 73(7.0) 0.23 0.49
LDL (mg/dl) 129(6.02) 134(2.82) 0.46 111(7) 107(2.7) 0.55
HDL size (nm) 9.35(0.06) 9.36(0.04) 0.93 9.13(0.1) 9.15(0.1) 0.88 0.91
LDL size (nm) 21.6(0.05) 21.4(0.06) 0.03 21.3(0.1) 21.1(0.1) 0.37 0.02
APOC3 (mg/dl) 8.27(0.88) 11.2(1.05) 0.034 7.52(1.6) 11.5(1.5) 0.12 0.03
ApoA-1 (mg/dl) 186(5.25) 190(4.02) 0.57 174(9.6) 154(5.6) 0.12 0.34
ApoB (mg/dl) 102(3.77) 101(3.3) 0.93 99.6(5.7) 93.6(2.9) 0.37 0.47
Results presented as mean (SE).
CC, homozygous for ( 641) C; CA/AA, homozygous and heterozygous for ( 641) A.
ApoA-1, apolopoprotein A-1; ApoB, apolipoprotein B; BMI, body mass index; VLDL, very low density lipoproteins.
DOI: 10.1371/journal.pbio.0040113.t001
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Conserved Pathway for Extreme LongevityFirst, serum APOC3 levels were signiﬁcantly (;30%) de-
creased in our participants with the favorable APOC3
genotype. Second, lipid proﬁles were altered in the expected
(favorable) direction in participants with this genotype.
Finally, this favorable genotype was associated with reduced
insulin resistance and less hypertension. These ﬁndings
s u g g e s tt h a tt h eAPOC3 genotype may have favorable
pleiotrophic effects on a number of cardiovascular traits
and mortality.
Interestingly, while a recent study found that the pheno-
typic effects of APOC3 polymorphisms are modiﬁed by
dietary polyunsaturated fatty acids [22], the interactions of
APOC3 levels with exercise, body mass index or other
environmental effect have not been well studied. Our
population by genotype had similar body mass index,
suggesting that body weight is not strongly modulated by
genotype.
The APOC3 gene is located on the long arm of Chromo-
some 11q23, in tandem with the apolipoprotein A1 and A4
genes [8,26]. The APO A1-C3-A4-A5 gene cluster has been
studied extensively in relation to lipoproteins and CVD, and
most recently in the oldest old [8,27,28]. Given LD within this
gene cluster, we cannot rule out the possibility that the
associations we have demonstrated may be due to other
f u n c t i o n a lS N Pw i t h i nt h i sg ene cluster. However, our
observation that the APOC3  641 CC genotype associates
with APOC3 levels suggests that this is a functional SNP or is
marking a functional SNP within this gene. Further func-
tional studies will be required to determine if this promoter
variant directly results in a decrease in transcription.
Our haplotype analysis revealed a 2-SNP haplotype span-
ning both APOA4 and APOC3. One haplotype, AA in SNPs
(rs675 and rs2542052, respectively), was found to be signiﬁ-
cantly more prevalent among controls, whereas the AC
haplotype was signiﬁcantly more prevalent among centenar-
ians. The association between these two genes and plasma
lipids levels in populations has been reported elsewhere
[8,27,28]. Thus, sequence variants in partial LD that constitute
one or more haplotypes across more than one of these
apolipoprotein genes may inﬂuence longevity. However, our
ﬁndings that Apolipoprotein A1 and Apolipoprotein B levels
Figure 5. Survival Analysis according to APOC3 Genotypes
Of the 381 participants we genotyped since 1998, 64 had the  641 CC
genotype. To describe the relationship between genotype and death, we
plotted the Kaplan–Meier survival function estimates of probands and
controls by APOC3 genotype. Offspring were excluded in this analysis
because all participants are currently alive and offspring genotype/
phenotype is not independent of the probands.
Log-Rank (p ¼ 0.0008); Wilcoxon (p ¼ 0.0007).
CC, homozygous for ( 641) C; CA/AA, homozygous and heterozygous for
( 641) A.
DOI: 10.1371/journal.pbio.0040113.g005
Figure 4. Insulin Sensitivity and Hypertension according to APOC3
C( 641)A Genotype
All include offspring plus controls.
(A) Insulin sensitivity.
(B) Hypertension.
*p ¼ 0.05
CC, homozygous for ( 641) C; CA/AA, homozygous and heterozygous for
( 641) A.
DOI: 10.1371/journal.pbio.0040113.g004
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Conserved Pathway for Extreme Longevityare not altered by APOC3 genotype, suggest that the effect of
the genotype on the lipoprotein phenotype is mainly
mediated by mechanisms that do not involve alterations of
these apolipoproteins.
We have also shown an association of the APOC3  641 CC
genotype with increased insulin sensitivity as measured by
homeostatic model assessment. There are known polymor-
phisms of the APOC3 promoter within an insulin response
element that affect the level of transcription in response to
insulin in vitro [29]. In vivo, APOC3 transcription seems to be
dependant on insulin, among other factors [30]. Although the
 641 variant is not located within the insulin response
element of the APOC3 gene, the favorable CC genotype was
strongly associated with a better insulin sensitivity estimated
by the homeostatic model assessment. This can potentially
contribute to healthier aging in individuals with the APOC3
 641 CC genotype.
While the potential genetic pathways underlying human
exceptional longevity remain largely unknown, pathways
involved in lipoprotein metabolism appear to have important
inﬂuences on longevity in humans. First, the CVD-protective
phenotypes of high HDL and large lipoprotein particles sizes
are dramatically expressed in our centenarians, and were
conﬁrmed in Japanese centenarians [31], and oldest old
Italians [32]. Second, a variant in the CETP gene [6] is over-
represented in our centenarians, a ﬁnding that was conﬁrmed
in oldest old Italians [32]. Low CETP levels, which were
explained in part by this CETP variant, were observed in our
study [6] and in Japanese centenarians [31]. Sequence variants
in another lipoprotein gene, the microsomal transfer protein
gene, were implicated in another study of centenarians [7].
This study adds APOC3 to the list of lipoprotein genes that
may inﬂuence exceptional longevity. Interestingly, all these
genes are involved in different steps of lipoprotein metab-
olism and could potentially be additive in their effects.
While the concept that alteration of gene expression or
function of a particular gene can alter lifespan has been
demonstrated convincingly in lower animal models, it is
important to determine if those same genes and mechanisms
are relevant to the complex biology of mammals and humans.
Evidence to support such a connection are the ﬁndings that
abnormal nematode daf-16 (a transcription factor) or daf-2
(insulin/IGF-1 receptor homolog) causes juvenile animals to
enter a state of diapause, called dauer, instead of achieving
adulthood, thereby extending lifespan [33]. Both of these
genes are part of the insulin–IGF-I signaling pathway, which
has been implicated in longevity in mice [34]. Notably the
expression of vitellogenin (yolk protein/apolipoprotein-like)
genes (vit-2 and vit-5) decreases as lifespan increases [35]. This
hypothesis has been independently examined in honeybees
where the vitellogenin lipoprotein is associated with both
modulation of immune function and longevity [36]. We
suggest that modulation of apolipoprotein expression could
represent one conserved mechanism of life extension
inﬂuencing lifespan across species from nematodes to
humans. Furthermore, one of the regulators of APOC3
expression is Forkhead Box O1 (FOXO-1), a forkhead tran-
scription factor that mediates insulin action [29,30], which is
the homolog of the nematode’s daf-16 [33,37]. Deletion of the
FOXO-1 binding site in mouse hepatocytes annuls the
inhibitory action of insulin on hepatic expression of APOC3,
and animals that constitutively express active FOXO-1 have
hypertriglyceridemia [38]. Whether this example is relevant
to longevity of mammalian models is not known.
Genetic determinants of human longevity are likely to be
multifactorial and polygenic. Thus, polymorphisms in apoli-
poproteins and related genes are likely to be only one of
several potential pathways in which genetic variants inﬂuence
longevity. Our approach—to exploit the potent selection of
favorable genotypes in exceptionally aged individuals—can
be extended to other candidate genes as well as genome-wide
analysis. Replications of observed associations of genotypes
with longevity, coupled with functional studies to deﬁne the
mechanisms whereby speciﬁc genotypes inﬂuence longevity-
associated phenotypes, will provide important new under-
standings of killing diseases and the aging process. These new
understandings could potentially provide insights into
preventive and therapeutic interventions for several age-
related diseases that impart signiﬁcant morbidity and mortal-
ity among elderly individuals.
Materials and Methods
Study design and participants. In this case-control study, Ashkenazi
Jews were recruited as described elsewhere [5,6]. The Ashkenazi
population is believed to have descended from a small group of
founders based on both historical records and modern genetic
evidence. The advantage of using founder populations is that the
genetic determinants of a particular disease may be more homoge-
neous and easier to deﬁne, and false positive results due to
population stratiﬁcation is less likely [39]. Indeed, speciﬁc mutations
in a number of disease genes (e.g., breast cancer gene 1, breast cancer gene
2, adenomatosis polyposis coli gene, hereditary prostrate cancer gene) have
been initially identiﬁed in the Ashkenazi population at prevalence
rates consistent with a founder effect [40–44]. Stratiﬁcation in these
studies has not been required, and indeed these genes were later
implicated in other populations, too [45,46].
Two hundred and thirteen probands with exceptional longevity
(157 females and 56 males, age 98.2 (0.36) y [mean (SE)], range 95–107
y; 48% over the age of 100 y) were recruited to participate in the
study. The participants’ ages were deﬁned by birth certiﬁcates or
dates of birth as stated on passports. Probands were required to have
been living independently when they were 95 y of age as a reﬂection
of good health, although at the time of recruitment they could be at
any level of dependency. In addition, probands were required to have
a child who was willing to participate in the study. The offspring
group consisted of 122 females and 94 males (age 68.3 [0.45] y, range
51–89 y). The control group included 258 participants derived from
two sources: Ashkenazi Jews from the general population recruited by
the Einstein Aging Study and spouses of the recruited offspring. The
study sample included 183 participants with mean age 71.3 (0.67) y,
57% female [47]. Spouses of offspring included 75 participants with
mean age 70.2 (1.17) y, 53% female. These controls as a comparison
group similar in age to the offspring are important to overcome the
limitation of a cross-sectional sample, because the effects of age on
genotype, phenotype (APOC3 levels, lipids etc.), and outcomes
(hypertension and longevity) are minimized. Written informed
consent was obtained and the study was approved by the Committee
on Clinical Investigations of the Albert Einstein College of Medicine.
Clinical evaluation. A research nurse visited the research partic-
ipants in the morning to obtain a medical history, perform a physical
examination, and draw a fasting venous blood sample. Standardized
health histories were obtained using a questionnaire. At that visit, the
offspring and the participating spouses underwent similar evalua-
tions, as previously described [5,6]. Systolic (ﬁrst phase) and diastolic
(ﬁfth phase) blood pressure were obtained twice, using a standard
sphygmomanometer with the patient sitting for at least ﬁve minutes,
and hypertension was deﬁned according to Joint National Commis-
sion VII guidelines [11]. EAS controls underwent a similar evaluation
in an outpatient research center at our institution. All blood samples
for centenarians, offspring, and controls were processed at the
General Clinical Research Center at Albert Einstein College of
Medicine, at the clinical laboratories of Monteﬁore Medical Center
Laboratories (Albert Einstein College of Medicine, Bronx, New York,
United States), and at LipoScience (Raleigh, North Carolina, Unites
States).
PLoS Biology | www.plosbiology.org April 2006 | Volume 4 | Issue 4 | e113 0567
Conserved Pathway for Extreme LongevityLipids and lipoproteins. Total plasma cholesterol, TG, HDL, LDL,
APOA1, and apolipoprotein B concentrations for study participants
were measured by standard automated methods at the clinical
laboratories of Monteﬁore Medical Center (coefﬁcient of variance
[CV]ranged2.5%–3.5%).APOC3concentrationsinhumanserumwere
measuredbyELISAusingacommerciallyavailablekit(WakoChemicals
USA, Richmond, Virginia, United States) (CV ranged 2%–5%).
LDL and HDL subclass levels and mean particle sizes were
determined for all participants by proton nuclear magnetic reso-
nance spectroscopy at LipoScience. Each nuclear magnetic resonance
measurement produces the concentrations of three LDL subclasses
and ﬁve HDL subclasses of varying size, as previously described [6]
(CV ranged between 3.3 and 5.4). Insulin levels were measured by
polyclonal immunoassay at the Hormone Assay Core of the Diabetes
Research and Training Center of the Albert Einstein College of
Medicine (CV of 8.4%).
APOC3 genotyping. A multilocus polymerase chain reaction–based
assay was utilized to genotype known polymorphisms of APOC3 on
Chromosome 11q: C( 641)A, C( 482)T, T( 455)C, C1100T, C3175G,
T3206G. Brieﬂy, DNA was ampliﬁed using multiplex reaction
containing biotinylated primer pairs. Ampliﬁed fragments within
each polymerase chain reaction product pool were then detected
colorimetrically with sequence-speciﬁc oligonucleotide probes im-
mobilized in a linear array on nylon membranes strips. Probe
speciﬁcities had previously been conﬁrmed by sequencing and by use
of DNA genotyped independently through other methods such as
restriction length polymorphism analysis [48].
Statistical analyses. Pairwise crude comparisons of lipid levels and
lipid particle sizes among the study groups were carried out using the
Mann-Whitney U-test because the distributions were skewed.
Calculations were carried out using SAS version 6.12 (SAS Institute,
Cary, North Carolina, United States) and Stata version 8.2SE
(StataCorp, College Station, Texas, United States). Analyses of lipid
parameters were stratiﬁed by sex, given that there are known
differences between female and male lipid proﬁles and cardiovas-
cular risks [49,50]. Results are expressed as mean (SE).
In order to take into consideration the false positive associations
resulting from multiple tests of the 66 SNP (Table S1), a Bonferroni
correction was applied to determine the proper level of statistical
signiﬁcance, p ¼ 0.05/66 ¼ 0.0007.
For a comparison of the difference in APOC3 C( 641)A genotype
frequencies between the groups, the chi-square test was performed.
Genotype frequencies of all SNP were found to be in Hardy-
Weinberg equilibrium. A (corrected) p-value less than 0.05 was
considered the threshold for statistical signiﬁcance. Given that this is
a relatively homogeneous population, stratiﬁcation was not applied,
except to control for gender effects as noted above. The haplotype
association test between cases (probands) and controls was performed
using Haploview 3.2 software (http://www.broad.mit.edu/personal/
jcbarret/haploview/index.php) [51].
The participants’ survival distribution was estimated by the
Kaplan-Meier method, and the signiﬁcance of the difference in
survival distribution among the groups was tested by means of a log
rank test. Wilcoxon statistics were calculated to test homogeneity
between the groups.
Supporting Information
Table S1. Genes and Their Associated SNP Genotyped for This Study
The reported values are percent in Control/Proband and its
signiﬁcance of the change (p-Value).
After Bonferroni correction only CETP-VV and APOC-3 CC remain
signiﬁcant (p , 0.0066).
Found at DOI: 10.1371/journal.pbio.0040113.st001 (135 KB DOC).
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